These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration. Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460 [TBL] [Abstract][Full Text] [Related]
4. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Perakslis ED; Van Dam J; Szalma S Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001 [No Abstract] [Full Text] [Related]
5. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Woosley RL; Myers RT; Goodsaid F Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457 [TBL] [Abstract][Full Text] [Related]
6. Can open-source drug R&D repower pharmaceutical innovation? Munos B Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458 [TBL] [Abstract][Full Text] [Related]
7. Precompetitive research: a new prescription for drug development? Woodcock J Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454 [No Abstract] [Full Text] [Related]
8. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Vallance P; Williams P; Dollery C Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455 [No Abstract] [Full Text] [Related]
9. New IGF drug stirs competition in growth factor segment. Ratner M Nat Biotechnol; 2005 Oct; 23(10):1192. PubMed ID: 16211044 [No Abstract] [Full Text] [Related]
10. Precompetitive activity to address the biological data needs of drug discovery. Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293 [No Abstract] [Full Text] [Related]
11. Europe fiddles while innovation burns. Frantz S Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115 [No Abstract] [Full Text] [Related]
12. Market watch: Biopharma deal-making in 2014: a record year for M&A value. Micklus A; Muntner S Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786 [No Abstract] [Full Text] [Related]
13. Indian generics companies go on spending spree. Jayaraman KS Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583 [No Abstract] [Full Text] [Related]
14. Deal watch: recent trends in deal-making. Dawkes A; Papp T Nat Rev Drug Discov; 2010 Dec; 9(12):909. PubMed ID: 21119724 [No Abstract] [Full Text] [Related]
15. Small molecule challenges dominance of TNF-alpha inhibitors. Sheridan C Nat Biotechnol; 2008 Feb; 26(2):143-4. PubMed ID: 18259158 [No Abstract] [Full Text] [Related]
16. [From drug cost to drug price: steps and decisional processes]. Bruyninckx M; Nourissier C Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715 [No Abstract] [Full Text] [Related]
17. Open innovation: share or die.. Talaga P Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629 [No Abstract] [Full Text] [Related]
18. In vogue with venture. Patou G Nat Biotechnol; 2011 Nov; 29(11):967-9. PubMed ID: 22175076 [No Abstract] [Full Text] [Related]
19. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia. Doran E; Alexander Henry D J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023 [TBL] [Abstract][Full Text] [Related]
20. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare. Ben-Asher D; Juris M J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154 [No Abstract] [Full Text] [Related] [Next] [New Search]